Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?

被引：0
|
作者：
Gianni, Caterina [1 ]
Nicolo, Eleonora [2 ]
Cristofanilli, Massimo [2 ]
机构：
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Dept Med Oncol, Breast & GYN Unit, Meldola, Italy
[2] Weill Cornell Med, Div Hematol Oncol, Dept Med, 1300 York Ave, New York, NY 10065 USA
来源：
TRANSLATIONAL BREAST CANCER RESEARCH | 2024年 / 5卷
关键词：
CDK4/6; inhibitors; early breast cancer (EBC); ribociclib; hormone receptor positive (HR+); PLUS ENDOCRINE THERAPY; PALBOCICLIB;
D O I：
10.21037/tbcr-24-41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies
    Chang, Chun-Ming
    Lam, Ho Yin Pekkle
    ANTICANCER RESEARCH, 2023, 43 (12) : 5283 - 5297
  • [32] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
    Forstmeyer, D.
    ONKOLOGE, 2016, 22 (07): : 507 - 508
  • [33] Efficacy of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors
    Mo, Hanjie
    Renna, Catherine E.
    Moore, Halle C. F.
    Abraham, Jame
    Kruse, Megan L.
    Montero, Alberto J.
    LeGrand, Susan B.
    Budd, G. Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [34] Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR plus MBC).
    Jain, Amit L.
    Mullins, Janice Nhan
    Poorman, Kelsey Anne
    Chaudhry, Amina
    Ranganath, Harsha Avinash
    Miller, Emily McCollum
    Valasareddy, Poojitha
    Smith, Justin R.
    Ryder, Julie
    Winerip, Michelle
    Schwartzberg, Lee S.
    Vidal, Gregory A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
    Elisa Agostinetto
    Luca Arecco
    Evandro de Azambuja
    Oncology and Therapy, 2024, 12 : 19 - 29
  • [36] Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR plus ) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
    Brett, Jamie O.
    Herman, Paige E.
    Mayer, Erica L.
    Bardia, Aditya
    Wander, Seth A.
    CURRENT BREAST CANCER REPORTS, 2022, 14 (04) : 222 - 232
  • [37] Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
    Agostinetto, Elisa
    Arecco, Luca
    de Azambuja, Evandro
    ONCOLOGY AND THERAPY, 2024, 12 (01) : 19 - 29
  • [38] CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update
    O'Sullivan, Ciara C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1657 - 1667
  • [39] Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
    Guarducci, C.
    Nardone, A.
    Feiglin, A.
    Migliaccio, I.
    Malorni, L.
    Bonechi, M.
    Benelli, M.
    Di Leo, A.
    Hodgson, G.
    Shapiro, G.
    Brown, M.
    Jeselsohn, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [40] CDK 4/6 Inhibitors and Stereotactic Radiation in the Management of Hormone Receptor-Positive Breast Cancer Brain Metastases
    Potluri, T.
    Figura, N. B.
    Oliver, D. E.
    Robinson, T. J.
    Etame, A. B.
    Tran, N.
    Liu, J. K.
    Soliman, H.
    Forsyth, P.
    Sahebjam, S.
    Yu, M.
    Han, H. S.
    Ahmed, K. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E86 - E86
12345